BRAF and colorectal carcinoma: As a tumor suppressor, miR-193a-3p promotes the efficacy of BRAF inhibitor dabrafenib (DAB) and MEK inhibitor trametinib (TRA), and enhances the anti-proliferative effect of combined therapy of DAB, TRA with cetuximab in CRC (47).